AGÕæÈ˹ٷ½

STOCK TITAN

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

PetMed Express (NASDAQ: PETS) has received a notification from Nasdaq on July 2, 2025, regarding non-compliance with listing rules due to delayed filing of its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

The company has until September 1, 2025 to submit a compliance plan to Nasdaq, which may grant an extension until December 29, 2025 to regain compliance. PetMeds previously filed a Form 12b-25 on June 16, 2025, citing the need for additional time to compile and analyze financial information. The notice has no immediate impact on the company's Nasdaq listing status.

PetMed Express (NASDAQ: PETS) ha ricevuto una comunicazione da Nasdaq il 2 luglio 2025 riguardante il mancato rispetto delle regole di quotazione a causa del ritardo nella presentazione del suo Rapporto Annuale sul Modulo 10-K per l'esercizio chiuso al 31 marzo 2025.

L'azienda ha tempo fino al 1° settembre 2025 per presentare a Nasdaq un piano di conformità, che potrebbe concedere una proroga fino al 29 dicembre 2025 per rientrare nei requisiti. PetMed Express aveva già presentato un Modulo 12b-25 il 16 giugno 2025, motivando la necessità di ulteriore tempo per raccogliere e analizzare le informazioni finanziarie. La comunicazione non ha impatto immediato sullo status di quotazione dell'azienda su Nasdaq.

PetMed Express (NASDAQ: PETS) recibió una notificación de Nasdaq el 2 de julio de 2025 por incumplimiento de las normas de listado debido a la presentación tardía de su Informe Anual en el Formulario 10-K correspondiente al año fiscal finalizado el 31 de marzo de 2025.

La compañía tiene hasta el 1 de septiembre de 2025 para presentar un plan de cumplimiento a Nasdaq, que podría otorgar una prórroga hasta el 29 de diciembre de 2025 para recuperar el cumplimiento. PetMed Express presentó previamente un Formulario 12b-25 el 16 de junio de 2025, señalando la necesidad de tiempo adicional para compilar y analizar la información financiera. La notificación no afecta de inmediato el estado de cotización de la empresa en Nasdaq.

PetMed Express (NASDAQ: PETS)ëŠ� 2025ë…� 7ì›� 2ì�, 2025ë…� 3ì›� 31ì� 종료ë� 회계연ë„ì—� 대í•� ì—°ë¡€ ë³´ê³ ì„�(Form 10-K) 제출 지연으ë¡� ì¸í•´ ìƒìž¥ 규정 미준ìˆ� 통지ë¥� 나스닥으로부í„� 받았습니ë‹�.

회사ëŠ� 2025ë…� 9ì›� 1ì�까지 ë‚˜ìŠ¤ë‹¥ì— ì¤€ìˆ� 계íšì� 제출해야 하며, ë‚˜ìŠ¤ë‹¥ì€ ì¤€ìˆ� 회복ì� 위해 최대 2025ë…� 12ì›� 29ì�까지 연장í•� ìˆ� 있습니다. PetMed ExpressëŠ� 2025ë…� 6ì›� 16ì¼ì— 재무 ì •ë³´ 수집 ë°� ë¶„ì„ì� 위한 추가 시간ì� í•„ìš”í•¨ì„ ì´ìœ ë¡� Form 12b-25ë¥� 제출í•� ë°� 있습니다. ì� 통지ëŠ� 회사ì� 나스ë‹� ìƒìž¥ ìƒíƒœì—� 즉ê°ì ì¸ ì˜í–¥ì� 미치지 않습니다.

PetMed Express (NASDAQ : PETS) a reçu une notification de Nasdaq le 2 juillet 2025 concernant un non-respect des règles de cotation en raison du retard dans le dépôt de son rapport annuel sur le formulaire 10-K pour l'exercice clos le 31 mars 2025.

La société dispose jusqu'au 1er septembre 2025 pour soumettre un plan de conformité à Nasdaq, qui pourrait accorder une prolongation jusqu'au 29 décembre 2025 pour retrouver la conformité. PetMed Express avait précédemment déposé un formulaire 12b-25 le 16 juin 2025, invoquant la nécessité de temps supplémentaire pour compiler et analyser les informations financières. Cette notification n'a pas d'impact immédiat sur le statut de cotation de la société sur Nasdaq.

PetMed Express (NASDAQ: PETS) erhielt am 2. Juli 2025 von der Nasdaq eine Mitteilung über die Nichteinhaltung der Börsenregeln aufgrund der verspäteten Einreichung ihres Jahresberichts auf Formular 10-K für das am 31. März 2025 endende Geschäftsjahr.

Das Unternehmen hat bis zum 1. September 2025 Zeit, einen Compliance-Plan bei der Nasdaq einzureichen, die eine Verlängerung bis zum 29. Dezember 2025 gewähren kann, um die Einhaltung wiederherzustellen. PetMed Express hatte bereits am 16. Juni 2025 ein Formular 12b-25 eingereicht und dabei angegeben, dass zusätzliche Zeit zur Zusammenstellung und Analyse der Finanzdaten benötigt wird. Die Mitteilung hat keine unmittelbaren Auswirkungen auf den Nasdaq-Listing-Status des Unternehmens.

Positive
  • No immediate effect on Nasdaq listing or trading status
  • Company granted potential extension period up to December 29, 2025 to resolve the issue
Negative
  • Failure to file Form 10-K annual report on time
  • Non-compliance with Nasdaq Listing Rule 5250(c)(1)
  • Uncertainty regarding timing of Form 10-K completion

Insights

PetMed's Nasdaq deficiency notice signals compliance risk requiring resolution within 180 days to maintain listing status.

PetMed Express has received a deficiency notice from Nasdaq for failing to file its annual 10-K report on time. While this notice doesn't immediately affect the company's listing status, it initiates a structured compliance timeline that investors should monitor carefully.

The company now has until September 1, 2025 to submit a compliance plan to Nasdaq. If the plan is accepted, PetMed could receive an extension until December 29, 2025 to file its delayed annual report. This represents the maximum 180-day grace period that Nasdaq typically grants for reporting deficiencies.

The root cause appears to be ongoing difficulties in completing the company's financial statements and related disclosures. PetMed previously filed a Form 12b-25 on June 16, 2025, indicating it couldn't file on time "without unreasonable effort or expense," followed by an 8-K filing on July 1, 2025 with additional details.

This type of filing delay raises several potential concerns: it could indicate internal control weaknesses, accounting complexities, or possibly more serious underlying issues requiring extended review. While the company states it's "working diligently" to complete its financials, the lack of a specific timeline beyond "as soon as practicable" creates uncertainty.

Should PetMed fail to regain compliance within the maximum extension period, it could face delisting proceedings, which would significantly impact share liquidity and investor confidence. The company's ability to resolve these reporting issues promptly will be crucial for maintaining its Nasdaq listing and market stability.

DELRAY BEACH, Fla., July 03, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®�) (NASDAQ: PETS) received on July 2, 2025, an expected notice (the “Notice�) from The Nasdaq Stock Market LLC (“Nasdaq�) indicating that, as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 (the “Form 10-K�), with the Securities and Exchange Commission (“SEC�), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule�), which requires timely filing of all required periodic financial reports with the SEC.

The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.

The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days, or until September 1, 2025, and following receipt of such plan, Nasdaq may grant an exception of up to 180 calendar days from the Form 10-K due date, or until December 29, 2025, for the Company to regain compliance. On June 16, 2025, the Company filed a Notification of Late Filing on Form 12b-25 indicating that it was unable, without unreasonable effort or expense, to file its Form 10-K by the prescribed due date because the Company is continuing to compile, review, and analyze the information necessary to complete its financial statements and related disclosures to be included in the Form 10-K, as more fully described in the Company’s Current Report on Form 8-K filed with the SEC on July 1, 2025.

While the Company can provide no assurances as to timing, the Company is working diligently to complete its financial statements for its fiscal year ending March 31, 2025, and the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Listing Rule.

About

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Through its PETS family of brands, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.

Forward-Looking Statements

This press release contains “forward-looking statements� within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,� “could,� “expect,� “project,� “outlook,� “strategy,� “intend,� “plan,� “seek,� “anticipate,� “believe,� “estimate,� “predict,� “potential,� “strive,� “goal,� “continue,� “likely,� “will,� “would� and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties, including: statements regarding the Company’s ability to complete the filing of the Form 10-K within the anticipated time period; the Company’s ability to regain compliance with Nasdaq listing standards; and the time required to complete the Company’s financial statements for its fiscal year ending March 31, 2025. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the SEC, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2024, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Investor Contact:
ICR, LLC
John Mills
Reed Anderson
(646) 277-1260
[email protected]


FAQ

Why did PetMed Express (PETS) receive a Nasdaq deficiency notice in July 2025?

PetMed Express received the notice because it failed to timely file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, violating Nasdaq Listing Rule 5250(c)(1).

Will PetMed Express (PETS) be delisted from Nasdaq due to the late filing notice?

No, the notice has no immediate effect on PETS' Nasdaq listing. The company has until September 1, 2025, to submit a compliance plan and may receive up to 180 days (until December 29, 2025) to regain compliance.

When is PetMed Express (PETS) expected to file its delayed Form 10-K?

While PetMeds has not provided a specific date, the company stated it is working diligently to complete the financial statements and plans to file the Form 10-K as soon as practicable.

What reasons did PetMed Express (PETS) give for the delayed 10-K filing?

The company stated it needs additional time to compile, review, and analyze information necessary to complete its financial statements and related disclosures, citing this requires unreasonable effort or expense to complete by the original deadline.
Petmed Express Inc

NASDAQ:PETS

PETS Rankings

PETS Latest News

PETS Latest SEC Filings

PETS Stock Data

67.55M
14.52M
21.81%
45.3%
8.22%
Pharmaceutical Retailers
Retail-drug Stores and Proprietary Stores
United States
DELRAY BEACH